Akums Drugs & Pharmaceuticals Q2 FY27: revenue up 31.9% to ₹1,342 Cr, net profit up 168.4% to ₹115 Cr
Results · Finvezto · 2 Nov 2026 · Akums Drugs & Pharmaceuticals (AKUMS)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 1,342 | +15.1% | +31.9% |
| Operating profit | 195 | +11.4% | +106.0% |
| Net profit | 115 | +13.5% | +168.4% |
| Operating margin | 14.5% | -0.5 pp | +5.2 pp |
| Net margin | 8.5% | -0.1 pp | +4.3 pp |
Key points
- Akums Drugs and Pharmaceuticals reported consolidated revenue of Rs 1,342 crore for Q2 FY27, up 31.9% year-on-year, with EBITDA rising 106% to Rs 195 crore and profit after tax jumping 168% to Rs 115 crore. NSE filing
- Performance was driven by double-digit volume growth in CDMO alongside the acquisition of Oriflame India's manufacturing business for Rs 56 crore. NSE filing
- Revenue was ₹1,342 Cr, up 31.9% on a year earlier and up 15.1% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 12.7%, 13.1%, 15.0%, 14.5%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 68, 81, 101, 115.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.